~$990KFederal lobbying 2024 (OpenSecrets; no corporate PAC)
20+Brands in portfolio (Kleenex, Huggies, Scott, Kotex, Kimberly-Clark)
Filter:
2026
Kimberly-Clark federal lobbying; product legislation and forestry policy
By 2026, Kimberly-Clark continues to report federal lobbying on consumer and healthcare product legislation (menstrual product disclosure, diaper need, period equity), trade and tax policy, and forestry and sustainability. The company does not maintain a corporate PAC and does not use corporate funds for political contributions; lobbying is disclosed under the LDA. Trade associations and supply chain policy (pulp, packaging, climate) remain relevant to K-C's government relations. OpenSecrets and Senate LDA filings document activity.
K-C lobbying on menstrual and diaper legislation; trade and forestry
In 2025, Kimberly-Clark continues to lobby Congress on the Menstrual Products Right to Know Act, End Diaper Need Act, and PROUD Act (period equity and underserved populations), as well as trade, tax, and forestry-related policy affecting tissue and personal care. The company discloses lobbying expenditures in quarterly LDA reports; it does not operate a PAC. Sustainability and forests policy (FSC, recycled content, deforestation) align with K-C's public commitments and can involve engagement with agencies and legislators.
Kimberly-Clark reports ~$990K federal lobbying; menstrual and diaper bills
In 2024, Kimberly-Clark reported approximately $990,000 in federal lobbying (OpenSecrets), including internal lobbying, retained consultants, and trade association dues. Lobbying topics included the Menstrual Products Right to Know Act, the End Diaper Need Act of 2023 (S.2879), and the PROUD Act (period equity). The company does not sponsor a corporate PAC and does not use corporate funds for political contributions; it publishes an annual Government Relations Disclosure. Forestry and sustainability policy were also part of the company's policy engagement.
K-C lobbying on diaper need, period equity, and product regulation
In 2023, Kimberly-Clark lobbied on federal legislation related to diaper need and period equity, including the End Diaper Need Act and the PROUD Act, which would support access to menstrual and diaper products for underserved communities. The company also engaged on trade, tax, and regulatory issues affecting consumer and professional products (Kleenex, Huggies, Kotex, Scott, etc.). Kimberly-Clark continued its policy of no corporate PAC and no corporate political contributions; lobbying was disclosed under the Lobbying Disclosure Act.
Kimberly-Clark federal lobbying; consumer product and trade policy
In 2022, Kimberly-Clark engaged in federal lobbying on consumer product legislation, trade policy, and issues affecting the tissue, personal care, and professional segments. The company filed quarterly lobbying reports with Congress; it does not operate a PAC or make corporate political contributions. Supply chain, tariffs, and forestry/sustainability policy remained relevant to K-C's operations and were reflected in disclosure reports. State-level lobbying (e.g. incentives, workforce) occurred where the company had manufacturing or distribution presence.
K-C lobbying on COVID response, supply chain, and product legislation
In 2021, Kimberly-Clark lobbied on issues related to COVID-19 response, supply chain, and consumer and professional product regulation. The company's tissue and hygiene products were relevant to pandemic preparedness and healthcare settings. Federal lobbying disclosure continued under the LDA; K-C did not operate a corporate PAC. Trade, tax, and forestry policy were also part of the government relations agenda. State lobbying in Wisconsin and other states where K-C had facilities could touch on incentives and workforce development.
Kimberly-Clark federal lobbying; no PAC; trade and product policy
In 2020, Kimberly-Clark continued to report federal lobbying on trade, tax, and consumer product–related legislation. The company maintained its policy of no corporate PAC and no corporate funds for political contributions; employee participation in the political process was subject to the company's Code of Conduct and Anti-Corruption Policy. Lobbying disclosure was filed with Congress. Forestry, packaging, and sustainability policy could align with K-C's sustainability goals and supply chain commitments. State-level activity was reported where applicable.
K-C lobbies Wisconsin for $131K on jobs incentive bill; plant closures and retention
In 2019, Kimberly-Clark was reported to have spent approximately $131,000 lobbying the Wisconsin state legislature in support of a jobs incentive bill aimed at retaining the company's Cold Spring facility in Fox Crossing. The proposed tax credit package was designed to avert plant closures and preserve jobs; the measure drew debate over the cost to taxpayers versus job retention. K-C had announced restructuring and plant closures in prior years. The company continued federal lobbying on trade, tax, and product issues; it does not maintain a corporate PAC.
Kimberly-Clark restructuring and Wisconsin incentive debate; federal lobbying
In 2018, Kimberly-Clark announced a global restructuring that included plant closures and job cuts, including in Wisconsin. The state legislature debated a tax incentive package to encourage K-C to retain facilities; the company engaged in state lobbying. Federally, K-C continued to report lobbying on trade, tax, and regulatory issues affecting tissue, personal care, and professional products. The company did not operate a corporate PAC. Trade policy (tariffs, NAFTA/USMCA) was relevant to pulp, packaging, and cross-border supply chains.
K-C federal lobbying; tax reform and trade policy under new administration
In 2017, Kimberly-Clark lobbied on tax reform (Congressional and administration proposals that would affect corporate rates and international operations), trade policy, and regulatory issues. The company reported lobbying expenditure under the LDA; it did not maintain a corporate PAC. Forestry, environmental, and product regulation (FDA, CPSC where applicable) could be part of the disclosure. Restructuring and cost-cutting announced in the period had implications for state-level engagement (e.g. plant sites) in subsequent years.
Kimberly-Clark lobbying; trade, tax, and consumer product regulation
In 2016, Kimberly-Clark continued to file federal lobbying reports on trade, tax, and issues affecting consumer and professional products. The company did not operate a corporate PAC. Election-year dynamics did not change K-C's disclosed policy of no corporate political contributions. Lobbying could touch on international trade agreements, corporate tax, and regulations affecting tissue, hygiene, and healthcare products. State lobbying was limited in many jurisdictions; Wisconsin and other manufacturing states could see activity related to economic development.
K-C federal lobbying; limited state activity in Wisconsin
In 2015, Kimberly-Clark reported federal lobbying under the LDA. The company did not register a lobbyist in Wisconsin for the 2015–16 session and reported no state lobbying spending in 2013–14; historical Wisconsin spending had been modest (e.g. under $82,535 over two-year sessions). Federal focus included trade, tax, and regulatory matters. K-C did not maintain a corporate PAC. Forestry and sustainability policy gained prominence in corporate reporting and could be reflected in policy engagement over time.
K-C federal lobbying; healthcare and product policy context
In 2013, Kimberly-Clark reported federal lobbying in a year that included debate over healthcare reform (Affordable Care Act implementation) and fiscal policy. The company's professional and consumer healthcare-adjacent products (K-C Professional, Huggies, etc.) could be affected by Medicaid, Medicare, and hospital purchasing dynamics. Trade, tax, and general business regulation were disclosed in LDA reports. Kimberly-Clark did not maintain a corporate PAC. State lobbying remained limited in many jurisdictions.
Kimberly-Clark lobbying; election year; no PAC contributions
In 2012, Kimberly-Clark continued federal lobbying in an election year. The company did not operate a corporate PAC and did not make corporate political contributions; employee political activity was governed by company policy. LDA reports documented lobbying on trade, tax, and regulatory issues. Forestry, packaging, and sustainability were increasingly part of corporate reporting and could align with policy engagement. State lobbying in Wisconsin and other manufacturing states was reported where the company had facilities or sought incentives.
In 2011, Kimberly-Clark reported federal lobbying on trade, tax, and regulatory matters. The company did not maintain a corporate PAC. LDA disclosure reflected engagement with Congress and agencies on issues affecting the tissue, personal care, and professional segments. Healthcare and government procurement (K-C Professional) could be relevant to federal policy. State-level activity was limited in reported spending; Wisconsin had been a historical site for occasional lobbying (e.g. economic development, environmental compliance).
Kimberly-Clark lobbying; healthcare reform and business regulation
In 2010, Kimberly-Clark engaged in federal lobbying as Congress implemented the Affordable Care Act and debated financial and environmental regulation. The company's professional division (healthcare, government, and commercial) could be affected by Medicaid/Medicare and procurement policy. Trade, tax, and general business issues were disclosed in LDA reports. K-C did not operate a corporate PAC. Forestry and pulp sourcing were part of sustainability reporting and could involve policy engagement with agencies and legislators.
K-C lobbying during recession and stimulus; trade and tax
In 2009, Kimberly-Clark reported federal lobbying in a year of economic stimulus and healthcare reform debate. Trade policy, tax, and regulatory issues affecting consumer and professional products were disclosed. The company did not maintain a corporate PAC. State lobbying (e.g. Wisconsin) could touch on economic development and workforce programmes. Forestry and environmental policy remained relevant to K-C's supply chain and sustainability commitments. LDA filings documented expenditure and general issue areas.
Kimberly-Clark federal lobbying; election year; no PAC
In 2008, Kimberly-Clark continued federal lobbying in an election year. The company did not operate a corporate PAC and did not use corporate funds for political contributions. LDA reports reflected engagement on trade, tax, and regulatory issues. Consumer product safety (CPSC) and environmental regulation could be relevant to tissue and personal care. State lobbying in Wisconsin and other states was reported where K-C had manufacturing or distribution. The following year would bring stimulus and healthcare reform as major federal policy themes.
K-C federal lobbying; trade, tax, and product regulation
In 2007, Kimberly-Clark reported federal lobbying on trade, tax, and regulatory issues affecting its tissue, personal care, and professional businesses. The company did not maintain a corporate PAC. LDA disclosure documented lobbying expenditure and general issue areas. Wisconsin and other states with K-C facilities could see limited state-level activity. Forestry, packaging, and environmental policy were relevant to the company's supply chain and would become more prominent in sustainability and government relations in subsequent years.
Kimberly-Clark political influence at the turn of the millennium
By 2000, Kimberly-Clark was a major global producer of tissue, personal care (Kleenex, Huggies, Kotex, Scott), and professional products. The company engaged in federal lobbying under the Lobbying Disclosure Act (1995) and did not maintain a corporate PAC. Trade, tax, and regulatory issues affecting consumer and professional products were typical focus areas. State lobbying in Wisconsin (and other manufacturing states) had been reported in prior years, with spending modest compared to some peers. The following decades would see continued federal disclosure, state incentive debates (e.g. Wisconsin 2018–2019), and policy engagement on product legislation (diaper need, period equity) and sustainability (forestry).
Kimberly-Clark workforce and restructuring follow-through
By 2026, Kimberly-Clark completes the workforce and operational changes tied to its 2024 reorganization (new operating model, ~$1.5B restructuring costs, North America / International Personal Care / International Family Care and Professional). Cash costs were largely tied to workforce reductions. The USW and other unions have continued to call for worker consultation before restructuring. K-C’s global footprint includes unionized and non-union facilities in the U.S., including Wisconsin.
K-C shifts Kotex production overseas; USW cites ~100 job losses at Neenah
In 2025, Kimberly-Clark announced plans to move Kotex production from the Neenah Cold Spring facility to Vietnam and Malaysia. The company stated there would be no net job loss; the United Steelworkers disputed this, stating roughly 100 jobs would be eliminated. The move echoed the 2018–2019 restructuring when Cold Spring was kept open only after union concessions and state incentives. USW continued to push for advance consultation with workers on restructuring decisions.
Kimberly-Clark announces $1.5B reorganization and workforce reductions
In March 2024, Kimberly-Clark announced a major reorganization with approximately $1.5 billion in pre-tax restructuring costs over three years. The company moved from three geographic business segments to three new units: North America, International Personal Care, and International Family Care and Professional. About half of the costs (~$750M cash) were for workforce reductions; the company did not disclose job-cut numbers. The shift was driven by cost pressure, private-label competition, and supply chain modernization; transformation was expected to continue through 2026.
NLRB charge by USW Local 10-448 against Kimberly-Clark (Chester, PA)
In June 2023, USW Local 10-448 filed a charge with the National Labor Relations Board against Kimberly-Clark in Chester, Pennsylvania, alleging contract repudiation and unilateral changes under Section 8(a)(5) of the NLRA. The case (04-CA-319259) was closed in January 2024 following a withdrawal request. The dispute highlighted ongoing tensions between K-C and unionized workers over contract administration and restructuring-related changes at U.S. facilities.
K-C FORCE program and productivity; labor footprint
In 2022, Kimberly-Clark reported $290 million in savings from its FORCE (Focused On Reducing Costs Everywhere) program in its annual report. Productivity and cost initiatives affected staffing and operations across manufacturing and distribution. The company’s global workforce included unionized plants (e.g. USW in Wisconsin and elsewhere) and non-union facilities. Labor relations remained in focus as K-C continued to optimize its manufacturing footprint after the 2018–2019 restructuring.
Kimberly-Clark settles Black worker bias and retaliation suit
In 2021, Kimberly-Clark settled a race bias and retaliation lawsuit brought by a Black worker (reported in Law360). In a separate matter, Kimberly-Clark Pennsylvania LLC prevailed on summary judgment in a federal race discrimination case brought by a Black machinery operator who was terminated after refusing to provide a drug-test sample; the court rejected federal and state race discrimination claims. The cases underscored ongoing workplace diversity and discipline issues in K-C facilities.
COVID-19 and frontline workforce; K-C essential manufacturing
In 2020, Kimberly-Clark’s manufacturing and distribution workforce was classified as essential during the COVID-19 pandemic due to production of tissue, wipes, and personal care products (Kleenex, Huggies, Scott, Kotex). The company implemented safety protocols, leave policies, and pay practices for frontline workers. Unionized sites (e.g. USW) and non-union facilities negotiated or received pandemic-related accommodations. Supply chain and absenteeism pressures affected staffing and overtime across North American and international operations.
Neenah Nonwovens plant closes; USW global day of action vs. K-C
In 2019, Kimberly-Clark closed the Neenah Nonwovens plant by May 31, with 74 workers laid off between March and May. The Cold Spring mill in Fox Crossing remained open after union concessions and a state incentive package. The United Steelworkers held a global day of action (April 11), calling on K-C to consult workers before restructuring. The union criticized plant closures on four continents and job cuts despite company profitability.
K-C announces 5,000–5,500 job cuts and closure of two Wisconsin plants
In January 2018, Kimberly-Clark announced a global restructuring: 5,000–5,500 job cuts (12–13% of workforce) and the closure or sale of 10 plants worldwide. In Wisconsin, the company planned to close the Neenah Nonwovens facility and the Cold Spring mill in Fox Crossing (~610 jobs). Cold Spring was represented by United Steelworkers Local 2-482. After union concessions and state incentive talks, Cold Spring was kept open; Neenah Nonwovens closed in 2019.
Kimberly-Clark cost cuts and workforce optimization
In 2017, Kimberly-Clark continued cost-reduction and restructuring efforts that would lead to the major 2018 announcement. The company optimized manufacturing and supply chain and reduced overhead. Unionized sites in Wisconsin and elsewhere negotiated contracts under the shadow of competitive pressure and potential facility reviews. Workforce levels and benefits were in focus as K-C sought savings in North America and internationally.
K-C restructuring and labor footprint in North America
In 2016, Kimberly-Clark continued to streamline its North American and global operations. The company’s workforce included unionized paper and nonwovens plants (USW and others) and non-union facilities. Contract negotiations and productivity initiatives affected staffing and wages. The upcoming 2018 restructuring would later target several of these sites, including Wisconsin Cold Spring and Neenah.
Kimberly-Clark union contracts and Wisconsin operations
In 2015, Kimberly-Clark maintained unionized operations in Wisconsin (including Cold Spring with USW Local 2-482) and other states. Contract renewals addressed wages, benefits, and work rules. The company’s tissue, personal care, and professional segments relied on a mix of union and non-union labor. Productivity and automation investments were part of long-term cost plans that would later contribute to the 2018 restructuring announcement.
In 2014, Kimberly-Clark pursued cost and productivity programs affecting its global workforce. Manufacturing sites in the U.S. (including Wisconsin), Europe, and elsewhere faced competitive and cost pressure. Union negotiations in key plants addressed wages and benefits. The company’s focus on margin improvement would later culminate in the 2018 global restructuring and Wisconsin plant closure plans.
Kimberly-Clark labor relations and North American manufacturing
In 2013, Kimberly-Clark operated unionized and non-union facilities across North America. Labor relations included USW-represented mills and other unions. Wage and benefit negotiations, safety, and staffing levels were routine. The company’s tissue and personal care operations in Wisconsin remained a significant part of its U.S. footprint before the later restructuring.
In 2012, Kimberly-Clark continued cost-reduction programs that touched manufacturing and salaried workforce. Union contracts in Wisconsin and other states were renegotiated. The company’s global restructuring in later years would build on these efficiency efforts and lead to the 2018 announcement of plant closures and thousands of job cuts.
Kimberly-Clark unionized plants and contract talks
In 2011, Kimberly-Clark negotiated with unions at several U.S. plants, including paper and nonwovens facilities. Wages, healthcare, and pension or 401(k) benefits were typical issues. The company’s Wisconsin operations (Cold Spring, Neenah area) remained central to its North American tissue and personal care production before the 2018–2019 restructuring.
In 2010, Kimberly-Clark implemented restructuring that included job reductions and facility changes in North America and elsewhere. The company cited economic conditions and the need to align capacity with demand. Unionized workers were affected by layoffs and plant consolidations. These moves were part of a longer pattern of cost and workforce optimization.
In 2009, Kimberly-Clark reduced its workforce in response to the recession and weak demand. Layoffs, furloughs, and voluntary separation programs were used in North America and other regions. Unionized sites negotiated over the impact of job cuts and plant idling. The company’s cost actions during the financial crisis set the stage for later restructuring waves.
In 2008, Kimberly-Clark announced job cuts and facility closures as part of a cost-reduction program. The company targeted thousands of positions across its global operations, including manufacturing and administrative roles. Unionized plants in the U.S. were among those affected. The restructuring reflected rising input costs and competitive pressure in tissue and personal care.
Kimberly-Clark labor at the turn of the millennium
By 2000, Kimberly-Clark had a large global workforce spanning tissue (Kleenex, Scott), personal care (Huggies, Kotex), and professional products. Union representation included the United Steelworkers at several U.S. paper and nonwovens plants, including in Wisconsin. The following decades would see repeated restructuring, job cuts (2008, 2010, 2018, 2024), plant closures, and high-profile disputes over Wisconsin facilities and outsourcing.
By 2026, Kimberly-Clark continues to face product liability, consumer, environmental (PFAS), and employment-related litigation. Past resolutions include the Cottonelle “flushable” wipes class action (final approval 2024) and PFAS suits over the New Milford facility and Huggies wipes. The company discloses material legal proceedings in SEC filings and defends or settles claims as appropriate. Patent, trademark, and commercial disputes remain routine for a global consumer and professional products company.
PFAS and flushable-wipes litigation follow-through
In 2025, Kimberly-Clark continues to defend or resolve litigation stemming from PFAS claims (Connecticut facility contamination, Huggies wipes) and the completed Cottonelle flushable wipes class action (final approval March 2024). The company has stated it does not use PFAS in U.S. consumer products and defends the allegations vigorously. Claims for damages, water filters, and medical monitoring in PFAS cases may proceed in state or federal court.
Flushable wipes settlement final approval; PFAS class actions filed
In 2024, Kimberly-Clark saw the Armstrong v. Kimberly-Clark “flushable” wipes class action receive final approval (March); the settlement was valued at up to $17.5 million ($13.5M to class members who bought recalled Cottonelle Flushable Wipes Feb–Dec 2020, plus prior refunds). Separately, a Connecticut class action alleged the New Milford plant (Kleenex, Huggies, Scott) contaminated properties and drinking water with PFAS. A California class action alleged Huggies Simply Clean baby wipes contain PFAS. K-C stated it does not use PFAS in U.S. consumer products and will defend vigorously.
In September 2023, the parties in Armstrong et al. v. Kimberly-Clark Corporation filed a settlement agreement in the U.S. District Court for the Northern District of Texas. The class action alleged that recalled Cottonelle Flushable Wipes were marketed as “flushable” but caused plumbing and environmental harm. Mediation had produced a mediator’s proposal accepted in March 2023. The settlement provided up to $13.5 million to class members (plus prior refunds). Kimberly-Clark did not admit wrongdoing, citing a desire to avoid protracted litigation. Final approval was granted in March 2024.
In 2022, the Armstrong v. Kimberly-Clark flushable wipes litigation moved forward in the Northern District of Texas. A Consolidated Amended Complaint was filed in March. The cases (Armstrong/Nadeau in Texas, Rothfeld in New York) had been consolidated in 2021 before Judge Barbara Lynn. Mediation sessions in 2021–2023 led to a settlement. Plaintiffs alleged that Cottonelle Flushable Wipes were misrepresented as flushable and caused blockages and damage; the recall had covered wipes from Feb–Dec 2020.
In July 2021, the Cottonelle flushable wipes class actions were consolidated in the Northern District of Texas (Judge Barbara Lynn). Plaintiffs Armstrong/Nadeau (Texas) and Rothfeld (Eastern District of New York) alleged economic and personal harm from wipes marketed as flushable but recalled. In a separate matter, Kimberly-Clarksettled a Black worker’s bias and retaliation lawsuit (Law360). The company also prevailed in a federal race discrimination case in Pennsylvania where an employee was terminated after refusing a drug test.
In October and November 2020, class actions were filed against Kimberly-Clark over recalled Cottonelle Flushable Wipes. Melissa Armstrong and Roland Nadeau sued in the U.S. District Court for the Northern District of Texas (Oct 16); Dawn Rothfeld filed a similar suit in the Eastern District of New York (Nov 19). Plaintiffs alleged the wipes were marketed as “flushable” but caused plumbing damage, sewer issues, and economic harm. The recall had covered wipes purchased between Feb 7 and Dec 31, 2020. The cases were later consolidated and settled for up to $17.5 million.
In 2019, Kimberly-Clark faced routine product liability, commercial, and intellectual property litigation. The company’s SEC 10-K typically discloses material legal proceedings, including environmental, antitrust, or product claims. The Cottonelle flushable wipes recall that would later spawn the Armstrong class action had not yet occurred; prior wipes or tissue-related claims could involve labeling or consumer fraud. Patent and trademark disputes are common in the tissue and personal care sectors.
In 2018, Kimberly-Clark disclosed various legal matters in its annual report, including environmental, product liability, and commercial disputes. The company is periodically named in consumer, employment, or antitrust matters. No single case dominated headlines; the major event of the year was the restructuring and Wisconsin plant closure announcement, which had labor and political rather than litigation focus. Intellectual property and contract disputes continued in the normal course of business.
In 2017, Kimberly-Clark was involved in patent, trademark, and product-related litigation typical for a global consumer and professional products company. The tissue, wipes, and diaper segments often see disputes over technology, labeling, and advertising. The company does not routinely disclose individual case details unless material; SEC filings summarize legal contingencies. Commercial and distributor disputes may also arise in North America and internationally.
In 2016, Kimberly-Clark reported legal proceedings and contingencies in its SEC filings. The company faces claims related to product liability, environmental matters, intellectual property, and employment. Outcomes are uncertain; the company accrues reserves when losses are probable and reasonably estimable. No single blockbuster settlement or verdict defined the year; litigation activity was in line with the company’s size and global footprint in tissue, personal care, and professional products.
In 2015, Kimberly-Clark disclosed legal proceedings in its annual report, including product liability, environmental, and general commercial litigation. The company maintains insurance and accrues reserves for likely losses. Patent and trademark suits are common in the industry. No major class action or landmark verdict was reported for this year; the later flushable wipes and PFAS litigation would emerge in the 2020s.
In 2014, Kimberly-Clark was party to various product liability, commercial, and IP disputes. The company’s tissue and personal care lines (Kleenex, Huggies, Kotex, Scott) generate occasional consumer or competitor litigation. Environmental and employment claims may be pending in multiple jurisdictions. SEC filings describe material litigation in general terms. The $6 million “tainted wipes” settlement reported by Law360 in a later period reflects the type of product claim the company may resolve from time to time.
In 2013, Kimberly-Clark reported legal proceedings in its 10-K, including product liability, environmental, antitrust, and commercial matters. The company is subject to lawsuits and regulatory actions in the U.S. and abroad. Reserves are established when losses are probable and estimable. Patent and trademark litigation in the consumer products space is routine. No single high-profile case dominated the year.
In 2012, Kimberly-Clark disclosed legal proceedings and contingencies in its annual report. Product liability, environmental, and commercial litigation are recurring. The company defends or settles claims as appropriate and does not admit liability in many settlements. Intellectual property disputes with competitors or licensors occur in the tissue, diaper, and wipes categories. Outcomes can affect margins and reputation but are rarely existential for a company of K-C’s size.
Kimberly-Clark product liability and IP litigation
In 2011, Kimberly-Clark was involved in product liability and intellectual property litigation. Consumer claims may allege defective design, failure to warn, or misleading advertising. Patent disputes in diapers, wipes, and tissue are common among major manufacturers. The company discloses material litigation in SEC filings and maintains insurance and reserves. No landmark verdict or settlement was widely reported for this year.
In 2010, Kimberly-Clark faced various legal proceedings, including product liability, environmental, and commercial disputes. The company’s global operations expose it to litigation in multiple jurisdictions. SEC 10-K filings describe material legal matters and the company’s assessment of potential losses. Reserves are updated as cases develop. Patent and trademark litigation is routine in the consumer and professional products industries.
In 2009, Kimberly-Clark disclosed legal proceedings and contingencies in its annual report. The company is subject to product liability, environmental, antitrust, and employment litigation. Losses are accrued when probable and reasonably estimable. No single major settlement or verdict was highlighted; the legal environment was consistent with prior years. The recession did not produce a wave of headline-making consumer or shareholder suits against K-C.
In 2008, Kimberly-Clark reported legal proceedings in its 10-K, including product liability, environmental, and commercial matters. The company is periodically sued by consumers, competitors, or regulators. Intellectual property disputes over diapers, tissue, and wipes technology are common. Reserves are maintained for probable losses. No blockbuster case defined the year; litigation was in line with the company’s size and product range.
Kimberly-Clark litigation at the turn of the millennium
By 2000, Kimberly-Clark was a major global producer of tissue (Kleenex, Scott), personal care (Huggies, Kotex), and professional products, and was subject to the usual range of product liability, commercial, and IP litigation. The following decades would see significant class actions, including the Cottonelle flushable wipes case (filed 2020, settled up to $17.5M) and PFAS suits over facility contamination and wipes. Employment and environmental claims have also been recurring.
Kimberly-Clark sustainability and environmental footprint
By 2026, Kimberly-Clark continues to pursue its 2030 sustainability goals: Natural Forest Free beyond 2030, 50% reduction in natural forest fiber use (from 2011 baseline), and 90% of tissue fiber from environmentally preferred sources (recycled, FSC-certified virgin, alternative fibers). The company’s revised Forest, Land & Agriculture Policy (2024) commits to no deforestation (cutoff Dec 31, 2020) and addresses climate and biodiversity. PFAS litigation and environmental claims at the New Milford facility remain in the spotlight; K-C denies using PFAS in U.S. consumer products.
PFAS litigation and New Milford environmental claims continue
In 2025, environmental and legal fallout from alleged PFAS contamination at Kimberly-Clark’s New Milford, Connecticut, facility continues. A new lawsuit was filed in October 2025 on behalf of a resident; plaintiffs allege smokestack emissions and legacy landfill (1969–2010) have contaminated groundwater and the Housatonic River. Testing has shown PFOS and PFOA in private wells above EPA standards. K-C states it does not use PFAS in U.S. consumer products and defends the claims. The company’s forest and climate goals (Natural Forest Free, 2030 targets) remain a separate pillar of its sustainability reporting.
Revised Forest, Land & Agriculture Policy; PFAS suits allege New Milford contamination
In 2024, Kimberly-Clark published a revised Forest, Land & Agriculture Policy (May), addressing deforestation, land conversion, forest degradation, and indigenous land rights and aligning with current regulation and disclosure. The policy commits to no deforestation as of Dec 31, 2020 and to sourcing only from legal sources. The company reported progress toward 2030 sustainability goals in its 2023 report and June 2024 investor release. Separately, a Connecticut class action alleged the New Milford plant (Kleenex, Huggies, Scott) has contaminated properties and drinking water with PFAS via smokestacks and a legacy landfill; well testing showed PFOS/PFOA above EPA levels. K-C denies using PFAS in U.S. consumer products.
K-C 2023 Sustainability Report; forests and climate progress
In 2023, Kimberly-Clark published its Global Sustainability Report, documenting progress toward 2030 goals: Natural Forest Free beyond 2030, 50% reduction in natural forest fiber use (2011 baseline), and 90% of tissue fiber from environmentally preferred sources (recycled, FSC virgin, alternative fibers). The company treats FSC as the most rigorous standard for virgin fiber and has had a fiber procurement policy in place for over a decade. Reporting aligns with SASB and GRI. Climate, water, and packaging are also covered; the New Milford PFAS allegations would surface in litigation in 2024.
In 2022, Kimberly-Clark continued to advance its sustainable fiber strategy: increasing recycled fiber, FSC-certified virgin wood, and alternative non-wood fibers while reducing natural forest fiber use. The company’s 2025 milestone included 50% reduction in natural forest fiber (from 2011) and 90% of tissue from environmentally preferred sources. Forestry and biodiversity efforts support climate and SDG goals (e.g. Life on Land). The New Milford facility’s historical landfill (closed 2010) would later be cited in PFAS contamination suits.
K-C 2025 fiber targets and environmentally preferred sourcing
In 2021, Kimberly-Clark worked toward its 2025 fiber targets: 50% reduction in natural forest fiber use (from 2011 baseline) and 90% of tissue fiber from environmentally preferred sources—recycled, FSC-certified virgin wood, and sustainable alternative non-wood fibers. The company’s long-standing fiber procurement policy aimed to minimize impact on natural forests (boreal and temperate). Climate, water, and waste goals were reported in annual sustainability disclosures. The legacy landfill at New Milford (used 1969–2010) remained part of the site’s history later cited in PFAS litigation.
Kimberly-Clark deforestation cutoff and forest policy
In 2020, Kimberly-Clark aligned its commitments with a Dec 31, 2020 cutoff for no deforestation in its supply chain, later formalized in the 2024 Forest, Land & Agriculture Policy. The company continued to increase use of recycled and FSC-certified fiber and to reduce reliance on natural forest fiber. Sustainability reporting covered climate, water, and packaging. The New Milford plant (Kleenex, formerly Huggies) and its historical landfill (closed 2010) would later be at the center of PFAS contamination allegations and well testing above EPA limits.
In 2019, Kimberly-Clark continued to implement its sustainable fiber strategy, prioritizing recycled content, FSC-certified virgin fiber, and alternative fibers to reduce pressure on natural forests. The company’s tissue and towel products (Kleenex, Scott) are major users of pulp; sourcing choices affect boreal and temperate forests. Sustainability reports documented progress on fiber mix and environmental metrics. Wisconsin plant closures and restructuring during 2018–2019 had implications for local emissions and waste; the company’s global environmental footprint remained under investor and NGO scrutiny.
In 2018, Kimberly-Clark pursued its fiber and forest sustainability goals amid a major restructuring that closed or sold plants globally. The company had committed to reducing natural forest fiber use and increasing environmentally preferred sources (recycled, FSC, alternatives). Tissue products (Kleenex, Scott) and personal care (Huggies, Kotex) drive significant pulp demand; responsible sourcing and certification (FSC) were reported in sustainability disclosures. Plant closures in Wisconsin and elsewhere had local environmental implications (land use, waste, emissions) while the company optimized its manufacturing footprint.
In 2017, Kimberly-Clark reported on sustainable fiber sourcing, recycled content, and forest impact in its sustainability materials. The company’s tissue and towel business depends heavily on wood pulp; FSC and recycled fiber targets were part of long-term environmental strategy. Climate, water, and waste metrics were disclosed. The New Milford facility (Kleenex, and historically Huggies) had used an on-site landfill until 2010; that legacy would later be cited in PFAS contamination lawsuits alleging seepage and water impacts.
In 2016, Kimberly-Clark continued to emphasize sustainable fiber sourcing and forest stewardship. The company had set goals to reduce natural forest fiber use and increase recycled and FSC-certified supply. Tissue (Kleenex, Scott) and personal care (Huggies, Kotex) drive pulp demand; environmental groups had historically pressured tissue makers on boreal forest sourcing. K-C’s sustainability report covered fiber, climate, water, and waste. The 2011 baseline for natural forest reduction would anchor later 2025 and 2030 targets.
In 2015, Kimberly-Clark reported on fiber sourcing, recycled content, and environmental performance. The company’s 2025 targets (50% reduction in natural forest fiber from 2011 baseline, 90% tissue from environmentally preferred sources) were in development or early execution. FSC certification and recycled fiber were priorities for tissue and towel lines. Climate and water use were part of sustainability reporting. Manufacturing sites, including New Milford, were subject to environmental permits and reporting.
Kimberly-Clark sustainable sourcing and forest policy
In 2014, Kimberly-Clark had a fiber procurement policy aimed at minimizing impact on natural forests and increasing use of recycled and certified virgin fiber. The company’s tissue and personal care businesses relied on large volumes of pulp; NGO campaigns had previously targeted tissue makers over boreal forest use. K-C’s sustainability disclosures covered fiber mix, climate, and water. The 2011 baseline for natural forest fiber reduction would underpin later 2025 and 2030 commitments (Natural Forest Free beyond 2030).
In 2013, Kimberly-Clark reported on fiber procurement, recycled content, and environmental performance. The company had set a 2011 baseline for natural forest fiber use that would drive later 2025 and 2030 targets. Tissue products (Kleenex, Scott) and diapers (Huggies) require substantial pulp and nonwovens; sourcing decisions affect forests and water. Sustainability reports addressed fiber mix, certification (FSC), climate, and waste. The New Milford plant had closed its on-site landfill in 2010; legacy impacts would later be raised in PFAS litigation.
In 2012, Kimberly-Clark continued to pursue sustainable fiber sourcing and forest stewardship. The company had established a 2011 baseline for natural forest fiber reduction; goals to increase recycled and FSC-certified fiber were part of its environmental strategy. Tissue (Kleenex, Scott) and personal care (Huggies, Kotex) drive significant pulp demand. Climate, water, and packaging were reported in sustainability materials. NGO pressure on tissue makers over boreal and old-growth forest use had influenced industry commitments.
K-C 2011 baseline for natural forest fiber reduction
In 2011, Kimberly-Clark established the baseline for its long-term goal to reduce natural forest fiber use by 50% by 2025. This baseline would anchor the company’s 2030 ambition to become Natural Forest Free across all products. The company increased focus on recycled fiber, FSC-certified virgin wood, and alternative non-wood fibers. Tissue (Kleenex, Scott) and towel products are major pulp users; sustainable sourcing became a pillar of K-C’s environmental and reputation strategy. The New Milford landfill had closed in 2010.
New Milford landfill closure; K-C fiber and environmental reporting
In 2010, Kimberly-Clark closed its 165-acre unlined landfill at the New Milford, Connecticut, facility, which had been used for manufacturing waste since 1969. The site produces Kleenex and had produced Huggies diapers (until 2004). The landfill would later be cited in PFAS contamination lawsuits alleging that paper sludge and other waste contributed to groundwater and river pollution. K-C continued to report on fiber sourcing, recycled content, and environmental performance; the 2011 baseline for natural forest fiber reduction would be set the following year.
In 2009, Kimberly-Clark reported on environmental performance, fiber sourcing, and sustainability. The company’s tissue and personal care operations (Kleenex, Huggies, Scott, Kotex) depend on large amounts of pulp and nonwovens; forest impact and certification (e.g. FSC) were emerging priorities. The New Milford landfill was still in use (it would close in 2010); the site would later be at the center of PFAS contamination allegations. Climate and water use were part of broader corporate responsibility reporting.
Kimberly-Clark forest and sustainability initiatives
In 2008, Kimberly-Clark continued to face pressure from environmental groups over tissue and towel sourcing from natural forests, including boreal and temperate regions. The company had begun to emphasize recycled fiber and certification (FSC) and to disclose environmental metrics. The New Milford facility was still using its on-site landfill (closed 2010); the site produced Kleenex and had produced Huggies. Sustainability and “green” packaging were increasingly part of corporate communications ahead of the 2011 baseline and 2025/2030 forest goals.
Kimberly-Clark environmental footprint at the turn of the millennium
By 2000, Kimberly-Clark was a major global producer of tissue (Kleenex, Scott), personal care (Huggies, Kotex), and professional products, with significant pulp demand and manufacturing waste. The New Milford plant had been producing Huggies (until 2004) and Kleenex and was using an on-site landfill (1969–2010) that would later be cited in PFAS contamination suits. The following decades would see a fiber procurement policy, a 2011 baseline, 2025/2030 forest goals (Natural Forest Free, 50% reduction in natural forest fiber, 90% environmentally preferred tissue), a 2024 Forest Policy, and PFAS litigation over New Milford.
Kenvue acquisition and Suzano IFP deal close; K-C transformation
In 2026, Kimberly-Clark expects to close two landmark transactions: the acquisition of Kenvue (Tylenol, Listerine, Aveeno, Neutrogena, Johnson’s) in a ~$48.7 billion cash-and-stock deal (shareholder approval Jan 2026; close expected 2H 2026), creating a ~$32B global health and wellness company; and the Suzano joint venture, with Suzano acquiring a 51% stake in K-C’s International Family Care and Professional tissue business (~$3.4B deal, close mid-2026). K-C will license Kleenex and Scott to the JV and retain 49%. The combined moves refocus K-C on personal care and health.
K-C to acquire Kenvue (~$48.7B) and sell majority of global tissue to Suzano (~$3.4B)
In November 2025, Kimberly-Clark announced an agreement to acquire Kenvue in a ~$48.7 billion cash-and-stock transaction (Tylenol, Listerine, Aveeno, Neutrogena, Johnson’s), creating a ~$32B global health and wellness leader; close expected 2H 2026. In June 2025, K-C agreed to sell a 51% stake in its International Family Care and Professional tissue business (Kleenex, Scott outside North America) to Suzano for ~$3.4 billion ($1.73B cash; K-C keeps 49%); over 40 regional brands divested, with Kleenex and Scott licensed to the JV. Close expected mid-2026.
Kimberly-Clark portfolio and restructuring; no major M&A
In 2024, Kimberly-Clark announced a major reorganization (~$1.5B restructuring costs) into North America, International Personal Care, and International Family Care and Professional, but did not complete a transformative acquisition or divestment. Portfolio focus remained on personal care (Huggies, Kotex) and tissue (Kleenex, Scott); the following year would bring the Kenvue acquisition agreement and the Suzano tissue JV. Bolt-on or small divestments were not highlighted in headlines.
In 2023, Kimberly-Clark did not announce a major acquisition or divestment. The company operated three business segments (North America, KC International) with tissue, personal care, and professional products. The 2024 reorganization and the 2025–2026 Kenvue and Suzano deals would later reshape the portfolio. Halyard Health (spun off in 2014) had been acquired by Owens & Minor in 2018; K-C no longer had a healthcare segment until the Kenvue deal.
Kimberly-Clark post-Softex integration; no major M&A
In 2022, Kimberly-Clark continued to integrate Softex Indonesia (acquired Oct 2020 for $1.2B), which added diaper and feminine-care brands (Sweety, Happy Nappy) in Southeast Asia. No major acquisition or divestment was announced. The company’s portfolio comprised North American and international consumer and professional tissue and personal care. The later Kenvue and Suzano transactions were not yet on the table.
In 2021, Kimberly-Clark continued to integrate Softex Indonesia (closed Oct 2020). In February, Kimberly-Clark Softex launched a new combined logo (Softex butterfly + K-C branding), reinforcing the merged identity in Indonesia’s diaper and feminine-care market. No other major M&A was announced. The company’s structure remained focused on consumer and professional tissue and personal care; the healthcare business had been spun off as Halyard in 2014.
Kimberly-Clark completes Softex Indonesia acquisition for $1.2 billion
In September 2020, Kimberly-Clark announced and in October 2020 completed the acquisition of Softex Indonesia for $1.2 billion (all cash) from shareholders including CVC Capital Partners Asia Pacific. Softex had ~$420M annual sales (~80% diapers, rest feminine and adult care) and held the #2 diaper position in Indonesia (brands Sweety, Happy Nappy). The deal strengthened K-C’s presence in Southeast Asia and Indonesia’s ~$1.6B diaper market. Financing was incremental debt and cash.
K-C plant closures and asset optimization; no major M&A
In 2019, Kimberly-Clark closed the Neenah Nonwovens plant (Wisconsin) and continued to optimize its manufacturing footprint after the 2018 restructuring (5,000–5,500 job cuts, 10 plants closed or sold). No major acquisition or divestment of a business unit was announced; the Softex deal would follow in 2020. The company sold or shuttered facilities as part of cost reduction rather than headline M&A. Halyard Health (spun off 2014) had been acquired by Owens & Minor in 2018.
Kimberly-Clark restructuring: plant closures and sales
In 2018, Kimberly-Clark announced a global restructuring: closure or sale of 10 plants and elimination of 5,000–5,500 jobs. In Wisconsin, the company planned to close Neenah Nonwovens and Cold Spring (Cold Spring was later kept open with state incentives and union concessions). Plant divestments and closures were part of portfolio and cost optimization rather than a single asset sale. Halyard Health (K-C’s former healthcare spin-off) was acquired by Owens & Minor in 2018; K-C had no stake.
In 2017, Kimberly-Clark did not announce a major acquisition or divestment. The company continued to optimize its consumer and professional portfolio (tissue, personal care, K-C Professional). The 2018 restructuring (plant closures and job cuts) was in preparation. Halyard Health (spun off in 2014) remained an independent company until its sale to Owens & Minor in 2018. K-C’s M&A focus was largely internal restructuring and efficiency rather than large deals.
In 2016, Kimberly-Clark operated as a focused consumer and professional products company two years after the Halyard Health spin-off (Oct 2014). No major acquisition or divestment was announced. The portfolio comprised North American and international tissue (Kleenex, Scott), personal care (Huggies, Kotex), and K-C Professional. The company would later pursue Softex (2020) and, much later, Kenvue and the Suzano tissue JV (2025–2026).
In 2015, Kimberly-Clark had been operating for one year without its healthcare business following the Halyard Health spin-off (completed Oct 31, 2014). K-C had used a one-time payment from Halyard to boost its share repurchase program to $2 billion. No major acquisition or divestment was announced during the year. The company focused on consumer tissue and personal care and K-C Professional; Halyard traded independently as HYH until acquired by Owens & Minor in 2018.
Kimberly-Clark spins off Halyard Health (healthcare business)
On October 31, 2014, Kimberly-Clark completed the spin-off of Halyard Health, Inc., its healthcare business. K-C shareholders received one share of Halyard for every eight shares of K-C held as of the Oct 23 record date (cash in lieu of fractional shares). Halyard began trading on the NYSE as HYH; K-C retained KMB. The separation let K-C focus on consumer and professional brands (Kleenex, Huggies, Kotex, Scott) and Halyard on infection prevention, pain management, and recovery. Halyard made a one-time payment to K-C; K-C increased its 2014 share repurchase program to $2 billion.
In 2013, Kimberly-Clark advanced plans to separate its healthcare business into an independent company. The spin-off would create Halyard Health (infection prevention, pain, recovery) and leave K-C focused on consumer and professional tissue and personal care. The board approved the spin-off in 2014; the distribution was completed Oct 31, 2014. No other major M&A was announced during the year.
In 2012, Kimberly-Clark continued to operate its healthcare segment alongside consumer and professional products. The company would later decide to spin off the healthcare business (Halyard Health, 2014). No major acquisition or divestment was announced. Portfolio optimization and cost programs were ongoing; the Halyard separation would be the next major structural change.
In 2011, Kimberly-Clark did not announce a major acquisition or divestment. The company operated consumer tissue, personal care, healthcare, and K-C Professional segments. The healthcare business would later be spun off as Halyard Health (2014). Restructuring and cost programs were ongoing; no transformative M&A was disclosed.
Kimberly-Clark restructuring and asset optimization
In 2010, Kimberly-Clark implemented restructuring that included job reductions and facility changes; some plants were closed or sold as part of cost and capacity alignment. No headline acquisition or divestment of a business unit was announced. The company’s healthcare segment remained part of K-C until the Halyard spin-off in 2014. Portfolio focus was on consumer and professional tissue and personal care.
In 2009, Kimberly-Clark reduced capacity and workforce in response to the recession; plant closures and consolidations were part of cost reduction rather than a strategic divestment. No major acquisition or divestment of a business was announced. The company retained its consumer, healthcare, and professional segments. The Halyard spin-off (2014) and later Softex (2020) and Kenvue/Suzano (2025–2026) would define future M&A.
In 2008, Kimberly-Clark announced job cuts and facility closures as part of a cost-reduction program. The company targeted thousands of positions and several plants; divestment or closure of facilities was part of portfolio and cost optimization. No major acquisition or business-unit sale was announced. The company continued to operate consumer tissue, personal care, healthcare, and K-C Professional; the healthcare spin-off (Halyard) would follow in 2014.
By 2000, Kimberly-Clark was a major global producer of tissue (Kleenex, Scott), personal care (Huggies, Kotex), and healthcare and professional products. The following decades would see the Halyard Health spin-off (2014), the Softex Indonesia acquisition ($1.2B, 2020), the Suzano joint venture for international tissue (~$3.4B, 2025–2026), and the Kenvue acquisition (~$48.7B, 2025–2026), transforming K-C into a health and wellness and personal care leader.
Kimberly-Clark product safety and recall oversight
By 2026, Kimberly-Clark continues to market Kleenex, Huggies, Kotex, Scott, and U by Kotex in the U.S., Canada, and globally. Consumer product recalls and market withdrawals are reported to the FDA (tampons, certain wipes) and Health Canada; medical devices (e.g. K-C Professional, KIMGUARD) are tracked in FDA device recall databases. Quality and safety remain under regulatory and consumer scrutiny.
K-C consumer products and regulatory recall reporting
In 2025, Kimberly-Clark’s consumer and professional products (tissue, wipes, tampons, diapers, exam gloves, container filters) remain subject to FDA and Health Canada recall and safety-alert reporting. Past voluntary recalls include the 2018 U by Kotex Sleek tampon recall and the 2020 Huggies Pull-Ups Toy Story 4 backpack recall in Canada. The company maintains quality and post-market surveillance for Kleenex, Huggies, Kotex, and Scott.
Kimberly-Clark product safety and recall landscape
In 2024, Kimberly-Clark continues to sell Kleenex, Huggies, Kotex, Scott, and professional products. Consumer complaints and litigation (e.g. alleged skin reactions to wipes) have drawn attention to product safety; official FDA or Health Canada recalls for K-C consumer products in 2024 were limited. Medical device recalls (e.g. KIMGUARD, exam gloves) are documented in FDA’s device recall database when applicable.
Huggies wipes safety complaints and product quality
In 2023, Kimberly-Clark faced consumer complaints and litigation over Huggies baby wipes, with some customers alleging that wipes caused skin burns or severe reactions in infants. Such reports can lead to FDA adverse-event filings and civil suits; no broad FDA recall of Huggies wipes was announced in 2023. The company markets wipes as suitable for sensitive skin; regulatory and legal scrutiny of ingredients and quality continues.
In 2022, Kimberly-Clark’s consumer products (Kleenex, Huggies, Kotex, Scott, U by Kotex) and professional/medical products remained under FDA and Health Canada oversight. Voluntary recalls and market withdrawals are posted on agency websites. Past notable recalls included the 2018 U by Kotex Sleek tampon recall (unraveling/defect) and the 2020 Huggies Pull-Ups Toy Story 4 backpack recall in Canada. Quality systems and post-market surveillance support ongoing compliance.
In 2021, Kimberly-Clark continued to supply tissue, personal care, and professional products globally. The 2018 U by Kotex Sleek tampon recall had been completed and terminated by the FDA. The company’s quality and regulatory teams monitor adverse events and cooperate with FDA and Health Canada on any new recalls or safety communications. Kleenex, Huggies, Kotex, and Scott remain flagship brands with ongoing quality controls.
Huggies Pull-Ups Toy Story 4 backpack recalled in Canada for scissors hazard
In January 2020, Kimberly-Clark recalled Huggies Pull-Ups® Plus training pants in Canada that included a promotional Toy Story 4 backpack. The backpacks could contain finishing scissors, posing laceration, abrasion, or puncture risk to children or caregivers. About 8,396 units (six variants, sizes 2T/3T–4T/5T) sold from August–October 2019 were affected; packaging was marked “Bonus Inside!” Health Canada posted the recall; consumers were told to inspect backpacks and contact Pull-Ups Customer Care if scissors were found.
U by Kotex Sleek tampon recall completion and Health Canada review
In 2019, the U by Kotex Sleek tampon recall announced in December 2018 was completed. The FDA terminated the recall; Health Canada concluded its review and found the voluntary recall satisfactory. The defect had caused tampons to unravel or come apart upon removal, with reports of infections, irritation, injury, and some symptoms potentially related to toxic shock. No other U by Kotex products were included; the company continued to sell Kotex and U by Kotex lines with updated quality controls.
Kimberly-Clark voluntary recall of U by Kotex Sleek tampons (U.S. and Canada)
In December 2018, Kimberly-Clark announced a voluntary recall of U by Kotex® Sleek® Tampons, Regular Absorbency, in the U.S. and Canada. Affected lots were manufactured Oct 7, 2016–Oct 16, 2018 and distributed Oct 17, 2016–Oct 23, 2018. The tampons had a quality defect causing them to unravel and/or come apart upon removal; some consumers needed medical attention to remove retained pieces. The company received reports of infections, vaginal irritation, localized injury, abdominal pain, nausea, and vomiting. The FDA classified it as a device recall; Health Canada posted the alert. Consumers could identify affected product by lot numbers on the package.
K-C consumer and medical device quality; pre-2018 Kotex recall period
In 2017, Kimberly-Clark sold U by Kotex Sleek tampons (some of which would later be included in the December 2018 recall for lots manufactured through October 2018). The company also markets Kleenex, Huggies, Scott, and professional/medical products. FDA and Health Canada oversee recalls and adverse-event reporting. K-C’s medical device lines (e.g. KIMGUARD container filters, exam gloves) have been subject to Class 2 device recalls in past years; consumer product quality is monitored continuously.
Kimberly-Clark U by Kotex Sleek manufacture period later recalled
In 2016, Kimberly-Clark manufactured U by Kotex Sleek tampons (Regular Absorbency) that would later be included in the December 2018 voluntary recall. The recall covered lots manufactured from October 7, 2016 through October 16, 2018; the defect (tampons unraveling or coming apart on removal) led to medical reports and regulatory action. During 2016, the company continued to sell Kleenex, Huggies, Kotex, and Scott with normal quality controls; the defect was identified and addressed in the 2018 recall.
In 2015, Kimberly-Clark’s consumer brands (Kleenex, Huggies, Kotex, Scott) and professional/medical products (KIMGUARD, exam gloves, wipes) were subject to FDA and, where applicable, Health Canada and CPSC oversight. The company has had Class 2 device recalls for products such as KIMGUARD container filters and synthetic powder-free vinyl exam gloves. Consumer product recalls and market withdrawals are reported to regulators when quality or safety issues are identified.
Kimberly-Clark professional and consumer product safety
In 2014, Kimberly-Clark marketed tissue (Kleenex, Scott), personal care (Huggies, Kotex), and professional/medical products. FDA device recalls for K-C professional equipment (e.g. container filters, exam gloves) are documented in the agency’s database when defects or compliance issues arise. Consumer product recalls for diapers, wipes, or tampons are reported to the FDA and Health Canada. Quality systems support ongoing monitoring and corrective action.
K-C tissue, personal care, and medical device oversight
In 2013, Kimberly-Clark’s broad product range—Kleenex, Huggies, Kotex, Scott, U by Kotex, and professional/medical devices—remained under FDA (and, for some items, CPSC and Health Canada) oversight. Voluntary recalls and market withdrawals are posted on regulatory sites when warranted. The company’s quality and regulatory teams track adverse events and cooperate with agencies. Past device recalls (e.g. exam gloves, container filters) illustrate the scope of K-C’s regulated product lines.
Kimberly-Clark product recalls and regulatory compliance
In 2012, Kimberly-Clark continued to sell Kleenex, Huggies, Kotex, Scott, and professional products in North America and globally. FDA and Health Canada maintain recall databases for consumer and medical products. K-C has historically had device recalls (e.g. exam gloves, KIMGUARD); consumer product recalls for tissue, wipes, diapers, or tampons are reported when quality or safety issues arise. The company’s global supply chain and quality systems support recall readiness.
In 2011, Kimberly-Clark’s consumer (Kleenex, Huggies, Kotex, Scott) and professional/medical product lines were subject to FDA, CPSC, and Health Canada recall and adverse-event reporting. Device recalls (e.g. vinyl exam gloves, container filters) are documented in FDA’s database. The company maintains quality and post-market surveillance; any recall or market withdrawal is coordinated with regulators and communicated to consumers and retailers.
Kimberly-Clark product safety and recall coordination
In 2010, Kimberly-Clark marketed tissue, personal care, and professional products across the U.S., Canada, and internationally. Regulatory oversight included the FDA (cosmetics, devices, certain consumer products), CPSC (consumer products where applicable), and Health Canada. Recalls and market withdrawals are reported to these agencies; K-C has had past device recalls (e.g. exam gloves) and maintains systems to identify, report, and remedy quality or safety issues.
K-C tissue, diapers, and professional product recalls
In 2009, Kimberly-Clark’s product portfolio—Kleenex, Huggies, Kotex, Scott, and K-C Professional—was subject to FDA, CPSC, and Health Canada recall and safety reporting. The company has had medical device recalls (e.g. synthetic powder-free vinyl exam gloves) documented in FDA’s device recall database. Consumer product quality issues, when identified, trigger voluntary recalls or market withdrawals in coordination with regulators.
Kimberly-Clark consumer and medical device recall oversight
In 2008, Kimberly-Clark sold Kleenex, Huggies, Kotex, Scott, and professional/medical products globally. FDA device recalls for K-C products (e.g. exam gloves, container filters) are recorded in the agency’s database when defects or nonconformities are found. Consumer product recalls for tissue, wipes, diapers, or feminine care are reported to the FDA and Health Canada as required. The company’s quality systems support detection, reporting, and remediation of safety or quality issues.
Kimberly-Clark product recalls at the turn of the millennium
By 2000, Kimberly-Clark was a major global producer of Kleenex, Huggies, Kotex, Scott, and professional/medical products. Consumer and medical device recalls were (and remain) reported to the FDA, CPSC, and Health Canada when quality or safety issues arise. The following decades would see notable voluntary recalls, including the 2018 U by Kotex Sleek tampon recall (unraveling/defect) and the 2020 Huggies Pull-Ups Toy Story 4 backpack recall in Canada, as well as FDA Class 2 device recalls for KIMGUARD and exam gloves.
